Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.25.
A number of equities research analysts have weighed in on NEOS shares. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. BMO Capital Markets cut their price target on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, August 12th. Finally, Cantor Fitzgerald cut their price target on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, June 12th.
NEOS stock traded down $0.04 during trading on Tuesday, hitting $1.39. The company had a trading volume of 400 shares, compared to its average volume of 186,121. The firm has a market capitalization of $70.12 million, a price-to-earnings ratio of -0.87 and a beta of 0.92. The business has a 50 day moving average of $1.78 and a 200 day moving average of $1.81. Neos Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $4.78. The company has a current ratio of 1.13, a quick ratio of 0.91 and a debt-to-equity ratio of 41.70.
Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA lifted its holdings in Neos Therapeutics by 1,749.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after acquiring an additional 9,552 shares during the last quarter. Weiss Asset Management LP acquired a new stake in Neos Therapeutics in the 2nd quarter valued at about $36,000. Acadian Asset Management LLC acquired a new stake in Neos Therapeutics during the 2nd quarter worth about $40,000. D. E. Shaw & Co. Inc. acquired a new stake in Neos Therapeutics during the 2nd quarter worth about $57,000. Finally, Rhumbline Advisers raised its holdings in Neos Therapeutics by 43.5% during the 1st quarter. Rhumbline Advisers now owns 53,730 shares of the company’s stock worth $140,000 after buying an additional 16,288 shares during the period. 45.86% of the stock is owned by institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.